VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.
VYNE Therapeutics Inc. (VYNE) is a Biotechnology company based in US with a market capitalization of $8.5M. Revenue grew 13.8% year-over-year and free cash flow was negative at -$33.1M. This page tracks VYNE's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.
US · 13 employees · IPO Jan 25, 2018
Valuation
Valuation & price
$0.67as of May 17, 2026· -53.8% vs 52w high
—
P/E ratio
Latest-FY diluted EPS
0.31
P/B ratio
Market cap ÷ book equity
—
Dividend yield
Price — last 12 months
Fundamentals
Key fundamentals
$8.5M
Market cap
13.8%
Revenue growth (YoY)
96.0%
Gross margin
-$33.1M
Free cash flow (USD)
-$29M
Net debt
Net cash position
0.4%
Share dilution
2/5
Graham criteria passed
Defensive-investor screen
Healthcare
Sector
Trajectory
Long-term trends
Revenue by year
2016 → 2025
Free cash flow by year
2016 → 2025
Gross margin by year
2021 → 2025
Value screen
Graham defensive-investor tests
0
Insider buys · 90 days
0
Insider sells · 90 days
Earnings
Last reported: May 15, 2026 (EPS $-0.08)
Next expected: not yet scheduled
On the tape
Recent SEC & insider activity
- 8-K eventJul 21, 2026Filing
Reverse Stock Split
- 8-K eventJul 17, 2026Filing
Special Meeting Results
- 8-K eventJul 14, 2026Filing
Reverse Merger Announcement
- 8-K eventJul 10, 2026Filing
Special Cash Dividend Declared
- 8-K eventMay 21, 2026Filing
Reverse Merger Announcement
- Quarterly reportMay 15, 2026Filing
10-Q Filed
Questions
Frequently asked questions
What is VYNE Therapeutics Inc.'s market cap?
VYNE Therapeutics Inc. (VYNE) has a market capitalization of $8.5M.
What is VYNE's P/E ratio?
A meaningful P/E ratio is not available for VYNE — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.
What is VYNE's price-to-book (P/B) ratio?
VYNE trades at 0.31 times book value per share.
When did VYNE Therapeutics Inc. last report earnings?
VYNE last reported earnings on May 15, 2026; the next date is not yet scheduled.
Are insiders buying VYNE stock?
SEC Form 4 filings show no open-market insider buys at VYNE Therapeutics Inc. in the last 90 days (0 sells).
Same arena
Related companies in Biotechnology
Timeline
Every filing, insider trade & earnings on a price-anchored timeline
Filing Analyzer
Search the actual 10-K / 10-Q text with AI research angles
News
Latest press coverage in one feed
Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.